News
GI Bleeding Lower With Apixaban vs Other DOACs in A-Fib
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
Your search for apixaban returned 107 results
MPR Weekly Dose Podcast
MPR Weekly Dose Podcast #135
FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended.
News
Apixaban Bests Rivaroxaban in “Emulated” Trial of Patients With Afib and VHD
Apixaban and rivaroxaban are both factor Xa inhibitors.
News
Apixaban Noninferior to Enoxaparin for Postoperative VTE Prophylaxis
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
Drugs in the Pipeline
Novel Factor XI Inhibitor Fast Tracked for Thrombosis Associated With Cancer
Abelacimab is a highly selective, fully human monoclonal antibody designed to inhibit both factor XI and its activated form, factor XIa.
Clinical Charts
Antiretroviral Contraindications and Drug Interactions
A list of contraindications and drug interactions for HIV medications.
News
Apixaban Tied to Lower Risk for Recurrent VTE in Dialysis Population
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
News
DOACs Cut Recurrent VTE in Adults With Cancer-Related Thrombosis
Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin
News
Rates of Recurrent VTE Compared for Apixaban, Rivaroxaban
Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban
